国药股份 (600511.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.4x

Market Cap

CNY 19.81B

MomentumView details →

1D Return

−0.53%

YTD Return

−5.91%

RSI (14)

50.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.4x

Market Cap

CNY 19.81B

RSI (14)

50.9

MomentumView details →

1D Return

−0.53%

YTD Return

−5.91%

ProfitabilityView details →

Gross Margin

6.53%

Net Margin

3.77%

EBITDA Margin

5.18%

ROE (TTM)

10.56%

ROA (TTM)

5.56%

Asset Turnover

1.46x

GrowthView details →

Revenue YoY

+4.15%

EPS YoY

+0.61%

FCF YoY

−82.56%

Revenue CAGR 3Y

+4.87%

EPS CAGR 3Y

+0.55%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.54

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.96%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

2.18x

Quick Ratio

1.82x

Div Yield

2.96%

Div Rate

CNY 0.80

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

53.31B

Net Income (TTM)

2.01B

Op. CF (TTM)

305.74M

Next earningsOct 28, 2026 →

Latest newsMore news →

China National Medicines Corporation Ltd reported its first-half 2026 results: revenue of 26.728 billion yuan, up 4.27% year-on-year; net profit attributable to shareholders of 880 million yuan, down 7.25% year-on-year.16d ago

Similar companies

辽宁成大600739.SH 九州通600998.SH 中国医药600056.SH Henry Schein, Inc.HSIC Shanghai Pharmaceuticals Holding Co., Ltd02607.HK Sinopharm Group Co. Ltd.01099.HK Find similar companies →

Latest newsMore news →

China National Medicines Corporation Ltd reported its first-half 2026 results: revenue of 26.728 billion yuan, up 4.27% year-on-year; net profit attributable to shareholders of 880 million yuan, down 7.25% year-on-year.16d ago